Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC's Partner Yakult Honsha Starts Clinical Phase I/II Study with Resminostat in NSCLC

Published: Thursday, July 25, 2013
Last Updated: Thursday, July 25, 2013
Bookmark and Share
The Phase I/II study will investigate safety and efficacy of resminostat/docetaxel combination vs. docetaxel alone as a novel treatment option for patients with advanced, metastatic, or recurrent NSCLC.

4SC AG has announced that the first patient has been treated with resminostat in a Japan-based Phase I/II lung cancer (non-small-cell lung cancer, NSCLC) clinical study conducted by its exclusive Japanese partner Yakult Honsha.

The multi-centre and randomized study will investigate safety and efficacy of resminostat in combination with the cancer drug docetaxel vs. docetaxel alone in up to 118 patients in total with advanced, metastatic, or recurrent NSCLC who have previously received one platinum-based chemotherapy.

The dose-escalation Phase I part of the study will assess safety, tolerability and pharmacokinetics as well as determine the maximum tolerated dose (MTD) and potential dose-limiting toxicities (DLT) of the resminostat/docetaxel combination in order to determine a recommended dose (RD) for the Phase II part.

The randomized Phase II part will compare the efficacy of docetaxel alone - a standard chemotherapeutic regimen for NSCLC - with the combination therapy of resminostat and docetaxel in the enrolled NSCLC patients.

In a 21 day cycle docetaxel (75 mg/m2 body surface area, administered intravenously on Day 1) will be given either as monotherapy in the control arm or in combination with resminostat (up to 600 mg/day, orally administered on Days 1-5) in the second study arm.

Depending on the nature of potential side-effects observed, the dose of docetaxel may be reduced. The primary endpoint of the Phase II part is progression-free survival (PFS), secondary endpoints include response rate (RR), overall survival (OS), and safety.

In 2011, 4SC granted an exclusive license to Yakult Honsha, the Japanese market leader in gastro-intestinal cancer therapeutics, for the development and commercialization of resminostat in Japan.

In 2012 Yakult Honsha started the clinical development of resminostat in Japan with a Phase I study in solid tumours followed in 2013 by a Phase I/II study in first-line treatment of advanced liver cancer (hepatocellular carcinoma, HCC).

Enno Spillner, Chief Executive Officer of 4SC AG, said: 'We very much appreciate that our partner Yakult Honsha has started developing resminostat in NSCLC. After HCC and CRC, this is now the third solid cancer indication in which our new epigenetic drug has been introduced into clinical evaluation. Lung cancer is the leading cause of cancer-related mortality around the world, so we are excited to follow the development of resminostat in yet another indication of both high medical need and large market potential.'

Bernd Hentsch, Chief Development Officer of 4SC AG, added: 'There is intriguing evidence in the literature that inhibition of histone deacetylases (HDACs) may be effective in the treatment of lung cancer. Although many drugs have been tested in NSCLC, the medical need in this indication is still very high due to the heterogeneity of this group of cancers and its relative insensitivity to standard chemotherapy regimens. Therefore, the combination approach applied in this study again attempts to make use of the so far observed good ability of resminostat to be combined with a variety of other standard anti-tumor agents.'


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC AG Discuss "Epigenetic Regulation of Immunogenicity" at 10th Scientific Symposium
"Epigenetic therapy a vital component in the fight against cancer".
Saturday, October 10, 2015
4SC Receives Funding from the Eurostars Programme
Three-year research programme in cooperation with two other European epigenetics companies funded.
Saturday, October 03, 2015
4SC Strengthens Patent Protection for its Epigenetic Cancer Drug Candidate 4SC-202
A selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.
Tuesday, August 18, 2015
4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
Friday, June 26, 2015
4SC Signs Licensing and Development Agreement with Menarini
Licensing partnership for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan.
Thursday, April 16, 2015
Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join 4SC AG
Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn.
Saturday, January 17, 2015
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucial role in cell division and tumour growth.
Friday, December 12, 2014
4SC Further Strengthens Patent Protection for its Lead Compound Resminostat
US Patent granted for the manufacturing process of resminostat.
Tuesday, October 21, 2014
4SC's Partner Yakult Honsha Completes Phase I Part of Clinical Study with Resminostat in NSCLC Patients
Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian NSCLC patients.
Saturday, October 11, 2014
CRELUX and 4SC Discovery Awarded Research Grant
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme.
Thursday, July 24, 2014
4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
Dr Erich Enghofer joins 4SC in the newly created position of Executive Vice President.
Friday, July 04, 2014
4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study
Company will present data from Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO.
Friday, May 30, 2014
4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC Expands Patent Protection for Epigenetic Anti-Cancer Compound
4SC AG announced that the company has significantly expanded international patent protection for 4SC-202 in the USA, China and Hong Kong.
Monday, July 15, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!